We provide the latest news
from the world of economics and finance
(RTTNews) - ChromaDex Corp. (CDXC) announced on Friday that the company's Nicotinamide Riboside Chloride or NRC has received the U.S. Food & Drug Administration's Orphan Drug Designation and Rare Pediatric Disease Designation for the treatment of patients with Ataxia Telangiectasia or AT.
The biotechnology company noted AT is a rare, progressive disease, causing neurological and immunological symptoms, eventually leading to cerebellar degeneration.
The designation comes as NRC improved AT scores and increased immunoglobulins, or antibodies, in the immune-compromised patients during the study. Also, the drug improved neuromotor coordination and eye movements in 90 percent of participants in the study.
Further, ChromaDex is planning to file an Investigational New Drug application for future human clinical trials for the use of NRC.
Currently, ChromaDex's stock is climbing 19.58 percent, to $3.42 over the previous close of $2.86 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.